Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02642029 · ClinicalTrials.gov registry record · NA
Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study
A NA study, sponsored by Mclean Hospital.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT02642029 is a NA study that has completed, run by Mclean Hospital. The registered enrollment target is 28 participants.
The verdict
NCT02642029, a NA study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The goal of this study is to use transcranial magnetic stimulation (TMS) to investigate the impact of modulating cerebellar activity on time perception, executive function, and mood and psychotic symptoms in psychosis patients (i.e., schizophrenia, schizoaffective disorder, and bipolar disorder with psychotic features). The investigators hypothesize that abnormally reduced activity in the cerebellum contributes to the abnormalities in patients, that cerebellum-mediated disruptions in time perception may partially underlie executive dysfunction and symptoms, and that cerebellar stimulation will normalize disease-relevant outcome measures.
Interventions
- DEVICE Sham TMS
- DEVICE Excitatory TMS
- DEVICE Inhibitory TMS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-02-18 |
| Est. Completion | 2019-06-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02642029
The ClinicalTrials.gov registry entry for NCT02642029 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham TMS is the first listed.
NCT02642029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02642029 about?
NCT02642029 is a clinical study titled "Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study". The goal of this study is to use transcranial magnetic stimulation (TMS) to investigate the impact of modulating cerebellar activity on time perception, executive function, and mood and psychotic symptoms in psychosis patients (i.e., schizophrenia, schizoaffective disorder, and bipolar disorder with...
What is the current status of trial NCT02642029?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2016-02-18. Estimated completion is 2019-06-14.
What interventions are being tested in trial NCT02642029?
The interventions under investigation include: Sham TMS (DEVICE), Excitatory TMS (DEVICE), Inhibitory TMS (DEVICE).
Who is sponsoring clinical trial NCT02642029?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.